Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Courtney Stene

Physician Assistant, Medical Overland Park, KS Physician Assistant

NPI 1831648112 CMS profile 11251089

11520 W 119Th St, Overland Park, KS 66213

Open in the dashboard

General payments

$22,324

836 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Courtney Stene of Overland Park, KS is reported in the CMS Open Payments database as having received $22,324 across 836 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,080 197
2024 General $5,936 184
2023 General $3,418 194
2022 General $3,231 155
2021 General $1,658 106

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Courtney Stene
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Courtney Stene were reported at $8,080. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Courtney Stene Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,658 $156 $41–$563 $132
2022 $3,231 $185 $55–$649 $149
2023 $3,418 $199 $58–$717 $160
2024 $5,936 $206 $62–$740 $164
2025 $8,080 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Sun Pharmaceutical Industries Inc. $7,976 65 payments
  2. AbbVie, Inc. $2,728 136 payments
  3. Janssen Biotech, Inc. $1,458 70 payments
  4. Pfizer Inc. $1,062 72 payments
  5. Lilly USA, LLC $952 54 payments
  6. Genzyme Corporation $913 36 payments
  7. UCB, Inc. $851 47 payments
  8. Amgen Inc. $766 37 payments
  9. Dermavant Sciences, Inc. $689 41 payments
  10. Regeneron Healthcare Solutions, Inc. $658 30 payments
  11. Other $4,271 248 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,348 827 payments
  2. Consulting Fee $5,300 4 payments
  3. Travel and Lodging $1,497 3 payments
  4. Education $179 2 payments
Products named General payments · program years 2021–2025
  1. Leqselvi $4,523 9 payments
  2. TREMFYA $1,533 73 payments
  3. DUPIXENT $1,267 48 payments
  4. RINVOQ $1,141 44 payments
  5. SKYRIZI $1,051 60 payments
  6. CIBINQO $895 67 payments
  7. LITFULO $798 54 payments
  8. Otezla $766 37 payments
  9. TALTZ $739 43 payments
  10. VTAMA $689 41 payments
  11. Other $9,171 561 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,035

Median for Physician Assistant: 241

Drug cost

$75,882

Median for Physician Assistant: $4,110

Branded share of claims

4.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 11 $55,476
Dutasteride Generic 123 $4,371
Minoxidil Generic 345 $3,523
Finasteride Generic 173 $1,842
Clobetasol Propionate Generic 53 $1,656
Fluocinolone Acetonide Fluocinolone/Shower Cap Brand 19 $1,539
Tacrolimus Generic 15 $1,415
Ketoconazole Generic 117 $1,176
Fluorouracil Generic 17 $1,111
Spironolactone Generic 39 $955

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$79,622

Of which drugs: $502

Medicare patients

324

Average age 72

Services billed

2,062

270 women, 54 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 50%
Osteoporosis 23%
Depression 19%
Diabetes 18%
Ischemic heart disease 17%
Cancer 17%
Chronic kidney disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 65 264 $191

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
$385 — —
DUPIXENT
$343 — —
TREMFYA
$338 — —
VTAMA
$270 — —
Otezla
$262 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

836 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record